Table 3 Relationship between PLR and clinicopathological features in GC patients living with HIV

Gender

1

 Male

26 (92.9%)

13 (100.0%)

 Female

2 (7.1%)

0 (0.0%)

Age

0.408

 Mean (SD)

58.2 (7)

56.8 (9.8)

 Median [MIN, MAX]

60 [44,70]

56 [44,76]

BMI

0.005

 Mean (SD)

21.7 (2.7)

19.7 (1.4)

 Median [MIN, MAX]

21.1 [15.1,26.6]

20.2 [17.3,21.7]

Hypertension

0.692

 No

21 (75.0%)

11 (84.6%)

 Yes

7 (25.0%)

2 (15.4%)

DM

0.399

 No

22 (78.6%)

12 (92.3%)

 Yes

6 (21.4%)

1 (7.7%)

TB

1

 No

26 (92.9%)

13 (100.0%)

 Yes

2 (7.1%)

0 (0.0%)

Smoking

0.398

 No

21 (75.0%)

12 (92.3%)

 Yes

7 (25.0%)

1 (7.7%)

Alcohol abuse

1

 No

24 (85.7%)

12 (92.3%)

 Yes

4 (14.3%)

1 (7.7%)

Hyperlipidemia

1

 No

23 (82.1%)

11 (84.6%)

 Yes

5 (17.9%)

2 (15.4%)

Duration of HIV infection

0.377

 Mean (SD)

22.7 (40.8)

32.5 (37.6)

 Median [MIN, MAX]

1 [0,132]

24 [0,108]

Duration of HIV treatment

0.113

 Mean (SD)

20.9 (37.2)

32.2 (37.2)

 Median [MIN, MAX]

0 [0,110]

24 [0,108]

Tumor Location

1

 Upper

5 (17.9%)

2 (15.4%)

 Middle

21 (75.0%)

10 (76.9%)

 Lower

2 (7.1%)

1 (7.7%)

Histology

0.719

 Signet ring cell

9 (32.1%)

3 (23.1%)

Her2 status

0.66

 0

13 (46.4%)

8 (61.5%)

 1 + 

11 (39.3%)

3 (23.1%)

 2 + 

4 (14.3%)

2 (15.4%)

SBR

0.694

 1

3 (10.7%)

2 (15.4%)

 2

8 (28.6%)

2 (15.4%)

 3

17 (60.7%)

9 (69.2%)

R0

1

 Yes

25 (89.3%)

12 (92.3%)

 No

3 (10.7%)

1 (7.7%)

T stage

0.657

 I

7 (25.0%)

2 (15.4%)

 II

1 (3.6%)

1 (7.7%)

 III

11 (39.3%)

4 (30.8%)

 IV

9 (32.1%)

6 (46.2%)

N stage

0.719

 Non-metastasis

9(32.1%)

3(23.1%)

 Metastasis

19(67.9%)

10(76.9%)

M stage

0.645

 Non-metastasis

25 (89.3%)

11 (84.6%)

 Metastasis

3 (10.7%)

2 (15.4%)

AJCC stage

0.173

 I-II

14(50.0%)

3(23.1%)

 III-IV

14(50.0%)

10(76.9%)